Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies announced the commencement of a proposed underwritten public offering of $200.0 million shares of its common stock and pre-funded warrants to purchase common stock. Jefferies, Goldman Sachs & Co. LLC, Piper Sandler, and Cantor are acting as joint book-running managers, with Baird serving as lead manager.
Key figures
- Shares Offered
- $200.0 million
- Underwriter option percent
- 15%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.